Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy

References

• Ngugi AK, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51(5):883–890.
   PubMed Web of Science ®Google Scholar
• Ngugi AK, Kariuki SM, Bottomley C, et al. Incidence of epilepsy: a systematic review and meta-analysis. Neurology. 2011;77(10):1005–1012.
   PubMed Web of Science ®Google Scholar
• De Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008;12(4):540–546.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother. 2006;6(3):397–406.
   PubMedGoogle Scholar
• Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–482.
   PubMed Web of Science ®Google Scholar
• Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990;323(8):497–502.
   PubMed Web of Science ®Google Scholar
• Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009. Epilepsia. 2009;50(Suppl 3):93–130.
   PubMed Web of Science ®Google Scholar
• Goldberg EM, Coulter DA. Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction. Nat Rev Neurosci. 2013;14(5):337–349.
   PubMed Web of Science ®Google Scholar
• Pitkanen A. Therapeutic approaches to epileptogenesis–hope on the horizon. Epilepsia. 2010;51(Suppl 3):2–17.
   PubMed Web of Science ®Google Scholar
• Loscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev. 2010;62(4):668–700.
   PubMed Web of Science ®Google Scholar
• Herman ST. Epilepsy after brain insult: targeting epileptogenesis. Neurology. 2002;59(9 Suppl 5):S21–26.
   PubMed Web of Science ®Google Scholar
• Pitkänen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol. 2011;10(2):173–186.
   PubMed Web of Science ®Google Scholar
• Zara F, Bianchi A. The impact of genetics on the classification of epilepsy syndromes. Epilepsia. 2009;50(Suppl 5):11–14.
   PubMed Web of Science ®Google Scholar
• Galanopoulou AS, Buckmaster PS, Staley KJ, et al. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia. 2012;53(3):571–582.
   PubMed Web of Science ®Google Scholar
• Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345–1356.
   PubMed Web of Science ®Google Scholar
• DiMario FJ Jr., Sahin M, Ebrahimi-Fakhari D. Tuberous sclerosis complex. Pediatr Clin North Am. 2015;62(3):633–648.
   PubMed Web of Science ®Google Scholar
• Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236–1241.
   PubMed Web of Science ®Google Scholar
• European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305–1315.
   PubMed Web of Science ®Google Scholar
• Van Slegtenhorst M, De Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805–808.
   PubMed Web of Science ®Google Scholar
• Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820–823.
   PubMed Web of Science ®Google Scholar
• Niida Y, Stemmer-Rachamimov AO, Logrip M, et al. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet. 2001;69(3):493–503.
   PubMed Web of Science ®Google Scholar
• Crino PB, Aronica E, Baltuch G, et al. Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology. 2010;74(21):1716–1723.
   PubMed Web of Science ®Google Scholar
• Qin W, Chan JA, Vinters HV, et al. Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events. Brain Pathol. 2010;20(6):1096–1105.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. The Lancet. 2008;372(9639):657–668.
   PubMed Web of Science ®Google Scholar
• White R, Hua Y, Scheithauer B, et al. Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers. Ann Neurol. 2001;49(1):67–78.
   PubMed Web of Science ®Google Scholar
• Valencia I, Legido A, Yelin K, et al. Anomalous inhibitory circuits in cortical tubers of human tuberous sclerosis complex associated with refractory epilepsy: aberrant expression of parvalbumin and calbindin-D28k in dysplastic cortex. J Child Neurol. 2006;21(12):1058–1063.
   PubMed Web of Science ®Google Scholar
• Weiner HL, Carlson C, Ridgway EB, et al. Epilepsy surgery in young children with tuberous sclerosis: results of a novel approach. Pediatrics. 2006;117(5):1494–1502.
   PubMed Web of Science ®Google Scholar
• Ma TS, Elliott RE, Ruppe V, et al. Electrocorticographic evidence of perituberal cortex epileptogenicity in tuberous sclerosis complex. J Neurosurg Pediatr. 2012;10(5):376–382.
   PubMed Web of Science ®Google Scholar
• Mohamed AR, Bailey CA, Freeman JL, et al. Intrinsic epileptogenicity of cortical tubers revealed by intracranial EEG monitoring. Neurology. 2012;79(23):2249–2257.
   PubMed Web of Science ®Google Scholar
• Ruppe V, Dilsiz P, Reiss CS, et al. Developmental brain abnormalities in tuberous sclerosis complex: a comparative tissue analysis of cortical tubers and perituberal cortex. Epilepsia. 2014;55(4):539–550.
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293.
   PubMed Web of Science ®Google Scholar
• Lipton JO, Sahin M. The neurology of mTOR. Neuron. 2014;84(2):275–291.
   PubMed Web of Science ®Google Scholar
• Inoki K, Li Y, Xu T, et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003;17(15):1829–1834.
   PubMed Web of Science ®Google Scholar
• Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801–1811.
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817–824.
   PubMed Web of Science ®Google Scholar
• McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595–1606.
   PubMed Web of Science ®Google Scholar
• Hinton RB, Prakash A, Romp RL, et al. International tuberous sclerosis consensus G. Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the international tuberous sclerosis consensus group. J Am Heart Assoc. 2014;3(6):e001493.
   PubMed Web of Science ®Google Scholar
• Datta AN, Hahn CD, Sahin M. Clinical presentation and diagnosis of tuberous sclerosis complex in infancy. J Child Neurol. 2008;23(3):268–273.
   PubMed Web of Science ®Google Scholar
• Wu JY, Peters JM, Goyal M, et al. Clinical electroencephalographic biomarker for impending epilepsy in asymptomatic tuberous sclerosis complex infants. Pediatr Neurol. 2016;54:29–34.
   PubMed Web of Science ®Google Scholar
• Jozwiak S, Kotulska K, Domanska-Pakiela D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. European J Paediatr Neurol: EJPN. 2011;15(5):424–431.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand Suppl. 2011;124(192):5–15.
   Google Scholar
• Curatolo P, Verdecchia M, Bombardieri R. Vigabatrin for tuberous sclerosis complex. Brain Dev. 2001;23(7):649–653.
   PubMed Web of Science ®Google Scholar
• Zeng L-H, Xu L, Gutmann DH, et al. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008;63(4):444–453.
   PubMed Web of Science ®Google Scholar
• Carson RP, Van Nielen DL, Winzenburger PA, et al. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin. Neurobiol Dis. 2012;45(1):369–380.
   PubMed Web of Science ®Google Scholar
• Meikle L, Pollizzi K, Egnor A, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008;28(21):5422–5432.
   PubMed Web of Science ®Google Scholar
• Goto J, Talos DM, Klein P, et al. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci U S A. 2011;108(45):E1070–1079.
   PubMed Web of Science ®Google Scholar
• Way SW, Rozas NS, Wu HC, et al. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex. Hum Mol Genet. 2012;21(14):3226–3236.
   PubMed Web of Science ®Google Scholar
• Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013;74(5):679–687.
   PubMed Web of Science ®Google Scholar
• Cardamone M, Flanagan D, Mowat D, et al. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr. 2014;164(5):1195–1200.
   PubMed Web of Science ®Google Scholar
• Baulac S, Ishida S, Marsan E, et al. Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations. Ann Neurol. 2015;77(4):675–683.
   PubMed Web of Science ®Google Scholar
• Lee JH, Huynh M, Silhavy JL, et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet. 2012;44(8):941–945.
   PubMed Web of Science ®Google Scholar
• Poduri A, Evrony GD, Cai X, et al. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron. 2012;74(1):41–48.
   PubMed Web of Science ®Google Scholar
• Parker WE, Orlova KA, Parker WH, et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med. 2013;5(182):182ra153.
   Google Scholar
• Nakashima M, Saitsu H, Takei N, et al. Somatic mutations in the MTOR gene cause focal cortical dysplasia type IIb. Ann Neurol. 2015;78(3):375–386.
   PubMed Web of Science ®Google Scholar
• D’Gama AM, Geng Y, Couto JA, et al. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Ann Neurol. 2015;77(4):720–725.
   PubMed Web of Science ®Google Scholar
• Scerri T, Riseley JR, Gillies G, et al. Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5. Ann Clin Transl Neurol. 2015;2(5):575–580.
   PubMed Web of Science ®Google Scholar
• Cheung KM, Lam CW, Chan YK, et al. Atypical focal cortical dysplasia in a patient with Cowden syndrome. Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi/Hong Kong Academy of Medicine. 2014;20(2):165–167.
   PubMed Web of Science ®Google Scholar
• Zhou J, Blundell J, Ogawa S, et al. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci. 2009;29(6):1773–1783.
   PubMed Web of Science ®Google Scholar
• Ljungberg MC, Sunnen CN, Lugo JN, et al. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis Model Mech. 2009;2(7–8):389–398.
   PubMed Web of Science ®Google Scholar
• Talos DM, Sun H, Zhou X, et al. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS One. 2012;7(5):e35885.
   PubMed Web of Science ®Google Scholar
• Chen S, Atkins CM, Liu CL, et al. Alterations in mammalian target of rapamycin signaling pathways after traumatic brain injury. J Cereb Blood Flow Metab. 2007;27(5):939–949.
   PubMed Web of Science ®Google Scholar
• Erlich S, Alexandrovich A, Shohami E, et al. Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis. 2007;26(1):86–93.
   PubMed Web of Science ®Google Scholar
• Guo D, Zeng L, Brody DL, et al. Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury. Plos One. 2013;8(5):e64078.
   PubMed Web of Science ®Google Scholar
• Butler CR, Boychuk JA, Smith BN. Effects of rapamycin treatment on neurogenesis and synaptic reorganization in the dentate gyrus after controlled cortical impact injury in mice. Front Syst Neurosci. 2015;9:163.
   PubMed Web of Science ®Google Scholar
• Hesdorffer DC, Logroscino G, Cascino G, et al. Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus. Ann Neurol. 1998;44(6):908–912.
   PubMed Web of Science ®Google Scholar
• Zeng L-H, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci. 2009;29(21):6964–6972.
   PubMed Web of Science ®Google Scholar
• Huang X, Zhang H, Yang J, et al. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol Dis. 2010;40(1):193–199.
   PubMed Web of Science ®Google Scholar
• Van Vliet EA, Forte G, Holtman L, et al. Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation. Epilepsia. 2012;53(7):1254–1263.
   PubMed Web of Science ®Google Scholar
• Wang X, Sha L, N S, et al. Deletion of mTOR in reactive astrocytes suppresses chronic seizures in a mouse model of temporal lobe epilepsy. Mol Neurobiol. 2016 Jan 5. [Epub ahead of print]
   Google Scholar
• Buckmaster PS, Lew FH. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J Neurosci. 2011;31(6):2337–2347.
   PubMed Web of Science ®Google Scholar
• Sliwa A, Plucinska G, Bednarczyk J, et al. Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Neurosci Lett. 2012;509(2):105–109.
   PubMed Web of Science ®Google Scholar
• Zhang B, McDaniel SS, Rensing NR, et al. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. Plos One. 2013;8(2):e57445.
   PubMed Web of Science ®Google Scholar
• Rensing N, Han L, Wong M. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex. Epilepsia. 2015;56:1088–1097.
   PubMed Web of Science ®Google Scholar
• Wong M. A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials. Expert Rev Neurother. 2013;13(6):657–669.
   PubMed Web of Science ®Google Scholar